Roche's Negative Parkinson Drug Results Don't Surprise -- Market Talk

Dow Jones12-19

0810 GMT - Roche's negative Parkinson trial readout doesn't surprise as the drug candidate had a high development risk all along, Vontobel analyst Stefan Schneider says in a note. The Swiss pharma giant's experimental Parkinson drug prasinezumab showed a numeric delay in slowing motor progression in early-stage Parkinson patients but still missed its primary goal in a mid-stage study. Vontobel estimated potential annual peak sales for 2.5 billion Swiss francs for prasinezumab which it didn't account for in its forecasts due to the high development risk associated with this drug, the analyst says. (helena.smolak@wsj.com)

(END) Dow Jones Newswires

December 19, 2024 03:10 ET (08:10 GMT)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2492143811?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-19 16:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2492143811","market":"hk","top_or_hot":-1,"title":"Roche's Negative Parkinson Drug Results Don't Surprise -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0810 GMT - Roche's negative Parkinson trial readout doesn't surprise as the drug candidate had a high development risk all along, Vontobel analyst Stefan Schneider says in a note. The Swiss pharma giant's experimental Parkinson drug prasinezumab showed a numeric delay in slowing motor progression in early-stage Parkinson patients but still missed its primary goal in a mid-stage study. Vontobel estimated potential annual peak sales for 2.5 billion Swiss francs for prasinezumab which it didn't account for in its forecasts due to the high development risk associated with this drug, the analyst says. (helena.smolak@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 19, 2024 03:10 ET (08:10 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Roche's Negative Parkinson Drug Results Don't Surprise -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRoche's Negative Parkinson Drug Results Don't Surprise -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-19 16:10 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>0810 GMT - Roche's negative Parkinson trial readout doesn't surprise as the drug candidate had a high development risk all along, Vontobel analyst Stefan Schneider says in a note. The Swiss pharma ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03165","symbol_name":"华夏欧优股对冲","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2492143811","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2492143811","pubTimestamp":1734595800,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0810 GMT - Roche's negative Parkinson trial readout doesn't surprise as the drug candidate had a high development risk all along, Vontobel analyst Stefan Schneider says in a note. The Swiss pharma giant's experimental Parkinson drug prasinezumab showed a numeric delay in slowing motor progression in early-stage Parkinson patients but still missed its primary goal in a mid-stage study. Vontobel estimated potential annual peak sales for 2.5 billion Swiss francs for prasinezumab which it didn't account for in its forecasts due to the high development risk associated with this drug, the analyst says. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03165":"华夏欧优股对冲","BK4007":"制药","RHHBY":"罗氏控股"},"translate_title":"罗氏帕金森病药物的负面结果并不令人意外——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RHHBY":0.9,"03165":0.6},"content_text":"0810 GMT - Roche's negative Parkinson trial readout doesn't surprise as the drug candidate had a high development risk all along, Vontobel analyst Stefan Schneider says in a note. The Swiss pharma giant's experimental Parkinson drug prasinezumab showed a numeric delay in slowing motor progression in early-stage Parkinson patients but still missed its primary goal in a mid-stage study. Vontobel estimated potential annual peak sales for 2.5 billion Swiss francs for prasinezumab which it didn't account for in its forecasts due to the high development risk associated with this drug, the analyst says. (helena.smolak@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 19, 2024 03:10 ET (08:10 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2492143811"}